Applied Proteomics

The API assets could enable more data-intensive, machine learning-based approaches to healthcare, said a principal at DiscernDx investor Khosla Ventures.

DiscernDx, which is backed by Khosla Ventures, stepped in to purchase API's assets after lender Square 1 Bank asserted a lien on the company late last year.

The firm is looking for outside partners to tackle test commercialization as it begins to bring its second-generation colorectal cancer assay to market.

The test, which the company aims to launch in the next few months, offers a boost in specificity compared to its existing SimpliPro Colon proteomic test.

Company officials said that they have seen favorable reorder rates and coverage decisions since launching the 11-protein colorectal cancer test in late 2015.

While the company had previously planned to launch on mass spec, it is using ELISA for the initial version of the test in a bid to bring it to market more quickly.

NEW YORK (GenomeWeb News) – Applied Proteomics today said that it will collaborate with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) on the discovery and development of molecular diagnostic tests for colon and pancreatic cancer.

Applied Proteomics said this week that it has closed a $28 million Series C financing round.

Bruker has appointed Thomas Bachmann to be president of its Bruker BioSpin Group.

NEW YORK (GenomeWeb News) – Applied Proteomics said today that it has closed a $28 million Series C financing round.

Pages

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.